These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38874618)

  • 1. GLP-1RA therapy increases circulating vascular regenerative cell content in people living with type 2 diabetes.
    Park B; Krishnaraj A; Teoh H; Bakbak E; Dennis F; Quan A; Hess DA; Verma S
    Am J Physiol Heart Circ Physiol; 2024 Aug; 327(2):H370-H376. PubMed ID: 38874618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodeling.
    Bakbak E; Verma S; Krishnaraj A; Quan A; Wang CH; Pan Y; Puar P; Mason T; Verma R; Terenzi DC; Rotstein OD; Yan AT; Connelly KA; Teoh H; Mazer CD; Hess DA
    Am J Physiol Heart Circ Physiol; 2023 Nov; 325(5):H1210-H1222. PubMed ID: 37773589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity.
    Terenzi DC; Bakbak E; Teoh H; Krishnaraj A; Puar P; Rotstein OD; Cosentino F; Goldenberg RM; Verma S; Hess DA
    Cardiovasc Res; 2024 Feb; 119(18):2858-2874. PubMed ID: 38367275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
    ; Tsukamoto S; Kobayashi K; Toyoda M; Tone A; Kawanami D; Suzuki D; Tsuriya D; Machimura H; Shimura H; Wakui H; Takeda H; Yokomizo H; Takeshita K; Chin K; Kanasaki K; Miyauchi M; Saburi M; Morita M; Yomota M; Kimura M; Hatori N; Nakajima S; Ito S; Murata T; Matsushita T; Furuki T; Hashimoto T; Umezono T; Muta Y; Takashi Y; Tamura K
    Diabetes Obes Metab; 2024 Aug; 26(8):3248-3260. PubMed ID: 38764356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
    J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.
    Anson M; Henney AE; Zhao SS; Ibarburu GH; Lip GYH; Cuthbertson DJ; Nabrdalik K; Alam U
    Diabetes Obes Metab; 2024 Jul; 26(7):2606-2623. PubMed ID: 38558280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?
    Bakbak E; Terenzi DC; Trac JZ; Teoh H; Quan A; Glazer SA; Rotstein OD; Al-Omran M; Verma S; Hess DA
    Rev Endocr Metab Disord; 2021 Dec; 22(4):1171-1188. PubMed ID: 34228302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial.
    Bakbak E; Krishnaraj A; Bhatt DL; Quan A; Park B; Bakbak AI; Bari B; Terenzi KA; Pan Y; Fry EJ; Terenzi DC; Puar P; Khan TS; Rotstein OD; Mazer CD; Leiter LA; Teoh H; Hess DA; Verma S
    Med; 2024 Jul; 5(7):718-734.e4. PubMed ID: 38552629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
    Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    Kintzoglanakis K; Diamantis C; Mariolis A; Paschou SA
    Diab Vasc Dis Res; 2024; 21(4):14791641241269743. PubMed ID: 39139128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
    Riley DR; Essa H; Austin P; Preston F; Kargbo I; Ibarburu GH; Ghuman R; Cuthbertson DJ; Lip GYH; Alam U
    Diabetes Obes Metab; 2023 Oct; 25(10):2897-2909. PubMed ID: 37385958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
    Lugner M; Sattar N; Miftaraj M; Ekelund J; Franzén S; Svensson AM; Eliasson B
    Cardiovasc Diabetol; 2021 Mar; 20(1):67. PubMed ID: 33752680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.
    de Oliveira Costa J; Lin J; Milder TY; Greenfield JR; Day RO; Stocker SL; Neuen BL; Havard A; Pearson SA; Falster MO
    Diabetes Obes Metab; 2024 Jul; 26(7):2787-2795. PubMed ID: 38618983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus.
    Hess DA; Terenzi DC; Trac JZ; Quan A; Mason T; Al-Omran M; Bhatt DL; Dhingra N; Rotstein OD; Leiter LA; Zinman B; Sabongui S; Yan AT; Teoh H; Mazer CD; Connelly KA; Verma S
    Cell Metab; 2019 Oct; 30(4):609-613. PubMed ID: 31477497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus.
    Nargesi AA; Jeyashanmugaraja GP; Desai N; Lipska K; Krumholz H; Khera R
    J Am Heart Assoc; 2021 Jul; 10(13):e021084. PubMed ID: 33998258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes.
    Busch RS; Kane MP
    Postgrad Med; 2017 Sep; 129(7):686-697. PubMed ID: 28657399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis.
    Hu M; Cai X; Yang W; Zhang S; Nie L; Ji L
    J Am Heart Assoc; 2020 Apr; 9(7):e015323. PubMed ID: 32223390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors.
    Liu J; Su X; Hao Y; Liu J;
    Sci Rep; 2024 Aug; 14(1):18290. PubMed ID: 39112571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.